XMRV and Prostate Cancer: a final perspective

Karen Sfanos; Amanda Aloia; Angelo De Marzo; Alan Rein

doi:10.1038/nrurol.2011.225

XMRV and Prostate Cancer: a final perspective

Karen Sfanos, Amanda Aloia, Angelo De Marzo, Alan Rein

Research output: Contribution to journal › Review article › peer-review

18 Citations (Scopus)

Abstract

XMRV was first described in 2006, when it was identified in samples isolated from prostate cancer tissues. However, studies have since shown that XMRV arose in the laboratory and was formed by genetic recombination between two viral genomes carried in the germline DNA of mice used during serial transplantation of the CWR22 prostate cancer xenograft. These new findings strongly imply that XMRV does not circulate in humans, but is only present in the laboratory. Thus, there is no reason to believe that it has any role in the etiology of prostate cancer or other diseases.

Original language	English
Pages (from-to)	111-118
Number of pages	8
Journal	Nature Reviews. Urology
Volume	9
Issue number	2
DOIs	https://doi.org/10.1038/nrurol.2011.225
Publication status	Published - Feb 2012

Access to Document

10.1038/nrurol.2011.225

Cite this

@article{59f513c2cc7940de9bf68b1c7ffb2511,

title = "XMRV and Prostate Cancer: a final perspective",

abstract = "XMRV was first described in 2006, when it was identified in samples isolated from prostate cancer tissues. However, studies have since shown that XMRV arose in the laboratory and was formed by genetic recombination between two viral genomes carried in the germline DNA of mice used during serial transplantation of the CWR22 prostate cancer xenograft. These new findings strongly imply that XMRV does not circulate in humans, but is only present in the laboratory. Thus, there is no reason to believe that it has any role in the etiology of prostate cancer or other diseases.",

author = "Karen Sfanos and Amanda Aloia and {De Marzo}, Angelo and Alan Rein",

year = "2012",

month = feb,

doi = "10.1038/nrurol.2011.225",

language = "English",

volume = "9",

pages = "111--118",

journal = "Nature Reviews. Urology",

issn = "1759-4820",

number = "2",

}

TY - JOUR

T1 - XMRV and Prostate Cancer: a final perspective

AU - Sfanos, Karen

AU - Aloia, Amanda

AU - De Marzo, Angelo

AU - Rein, Alan

PY - 2012/2

Y1 - 2012/2

N2 - XMRV was first described in 2006, when it was identified in samples isolated from prostate cancer tissues. However, studies have since shown that XMRV arose in the laboratory and was formed by genetic recombination between two viral genomes carried in the germline DNA of mice used during serial transplantation of the CWR22 prostate cancer xenograft. These new findings strongly imply that XMRV does not circulate in humans, but is only present in the laboratory. Thus, there is no reason to believe that it has any role in the etiology of prostate cancer or other diseases.

AB - XMRV was first described in 2006, when it was identified in samples isolated from prostate cancer tissues. However, studies have since shown that XMRV arose in the laboratory and was formed by genetic recombination between two viral genomes carried in the germline DNA of mice used during serial transplantation of the CWR22 prostate cancer xenograft. These new findings strongly imply that XMRV does not circulate in humans, but is only present in the laboratory. Thus, there is no reason to believe that it has any role in the etiology of prostate cancer or other diseases.

UR - http://www.scopus.com/inward/record.url?scp=84857035507&partnerID=8YFLogxK

U2 - 10.1038/nrurol.2011.225

DO - 10.1038/nrurol.2011.225

M3 - Review article

VL - 9

SP - 111

EP - 118

JO - Nature Reviews. Urology

JF - Nature Reviews. Urology

SN - 1759-4820

IS - 2

ER -

XMRV and Prostate Cancer: a final perspective

Abstract

Access to Document

Other files and links

Fingerprint

Cite this